Aqr Capital Management LLC Macrogenics Inc Transaction History

Aqr Capital Management LLC

$95.2 Billion
Q1 2025

A detailed history of Aqr Capital Management LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Aqr Capital Management LLC holds 232,399 shares of MGNX stock, worth $341,626. This represents 0.0% of its overall portfolio holdings.

Number of Shares

232,399

Previous 319,070 27.16%

Holding current value

$341,626

Previous $1.04 Million 71.53%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.26 - $3.49 $109,205 - $302,481	-86,671 Reduced 27.16%	232,399 $295,000
Q4 2024 Feb 14, 2025	SELL	$3.18 - $4.46 $332,456 - $466,275	-104,546 Reduced 24.68%	319,070 $1.04 Million
Q3 2024 Nov 14, 2024	BUY	$3.0 - $5.55 $841,365 - $1.56 Million	280,455 Added 195.9%	423,616 $1.39 Million
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $202,343 - $1.13 Million	61,131 Added 74.52%	143,161 $608,000
Q1 2024 May 15, 2024	SELL	$9.77 - $21.47 $491,860 - $1.08 Million	-50,344 Reduced 38.03%	82,030 $1.21 Million
Q4 2023 Feb 14, 2024	SELL	$4.48 - $10.11 $932,897 - $2.11 Million	-208,236 Reduced 61.14%	132,374 $1.27 Million
Q3 2023 Nov 14, 2023	BUY	$4.48 - $6.19 $538,778 - $744,427	120,263 Added 54.58%	340,610 $1.59 Million
Q2 2023 Aug 14, 2023	BUY	$4.62 - $7.54 $795,000 - $1.3 Million	172,078 Added 356.5%	220,347 $1.18 Million
Q1 2023 May 15, 2023	SELL	$4.82 - $7.24 $276,084 - $414,699	-57,279 Reduced 54.27%	48,269 $346,000
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $1.44 Million - $3.01 Million	-430,783 Reduced 80.32%	105,548 $708,000
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $1.19 Million - $2.07 Million	395,809 Added 281.67%	536,331 $1.86 Million
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $316,174 - $1.4 Million	140,522 New	140,522 $415,000
Q1 2022 May 16, 2022	SELL	$8.12 - $16.9 $168,351 - $350,387	-20,733 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.91 - $21.88 $223,710 - $307,654	-14,061 Reduced 40.41%	20,733 $333,000
Q3 2021 Nov 15, 2021	SELL	$19.74 - $28.7 $150,024 - $218,120	-7,600 Reduced 17.93%	34,794 $729,000
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $265,796 - $462,192	-12,972 Reduced 23.43%	42,394 $1.14 Million
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $11,223 - $19,621	591 Added 1.08%	55,366 $1.76 Million
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $106,036 - $142,038	5,463 Added 11.08%	54,775 $1.25 Million
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $1.22 Million - $1.56 Million	49,312 New	49,312 $1.24 Million
Q3 2019 Nov 14, 2019	SELL	$12.44 - $17.48 $197,422 - $277,407	-15,870 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$14.51 - $19.71 $54,427 - $73,932	3,751 Added 30.95%	15,870 $269,000
Q1 2019 May 14, 2019	SELL	$11.11 - $25.6 $164,639 - $379,366	-14,819 Reduced 55.01%	12,119 $218,000
Q4 2018 Feb 14, 2019	BUY	$11.75 - $21.42 $316,521 - $577,011	26,938 New	26,938 $342,000
Q4 2017 Feb 14, 2018	SELL	$16.19 - $20.3 $886,272 - $1.11 Million	-54,742 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$15.52 - $18.94 $849,595 - $1.04 Million	54,742	54,742 $1.01 Million

Others Institutions Holding MGNX

# of Institutions

117

Shares Held

51.4M

Call Options Held

45.1K

Put Options Held

143K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $90.3M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.

Account

Aqr Capital Management LLC Macrogenics Inc Transaction History